All In Biotech

Drug Trial Radar · NCT00288704

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs

Last checked: Nov 20, 2026Latest source record: Dec 6, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

Dec 2005

Primary completion

Jun 2008

Study completion Aug 2008

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Feb 8, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1). These mutations result in the body's overproduction of interleukin-1 (IL-1), a protein that stimulates the inflammatory process. IL-1 Trap (rilonacept) was designed to bind to the interleukin-1 cytokine and prevent it from binding to its receptors in the body.

Conditions

  • Familial Cold Autoinflammatory Syndrome (FCAS)
  • Familial Cold Urticaria
  • Muckle-Wells Syndrome (MWS)
  • Genetic Diseases, Inborn

Interventions

  • rilonacept 160 mgDrug

    Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).

  • PlaceboDrug

    Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.

  • rilonacept 160 mgDrug

    Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS)Time frame: Baseline (Days -21 to -1) and Week 6 (Days 21-42)
  2. Mean Change in Key Symptom Score (KSS) From Week 15 to Week 24 (During the Randomized Withdrawal Phase or Part B)Time frame: Week 15 through Week 24 (randomized withdrawal)

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Palm Desert, California

  • Site not named

    Upland, California

  • Site not named

    Jacksonville, Florida

  • Site not named

    Stuart, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Columbus, Georgia

  • Site not named

    Aurora, Illinois

  • Site not named

    Louisville, Kentucky

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Chesterfield, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    New York, New York

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Duncansville, Pennsylvania

  • Site not named

    Columbia, South Carolina

  • Site not named

    Greer, South Carolina

  • Site not named

    Chattanooga, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Waco, Texas

  • Site not named

    Cedar City, Utah

  • Site not named

    Forest, Virginia

  • Site not named

    Lakewood, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.